%D8%A8%D8%A7%D8%B3%D9%8A%D9%84%D9%8A%D9%83%D8%B3%D9%8A%D9%85%D8%A7%D8%A8%D8%A8%D8%A7%D8%B3%DB%8C%D9%84%DB%8C%D8%B3%DB%8C%D9%85%D8%A7%D8%A8BasiliximabBasiliximabBasiliximabBasiliximabBasiliximab%E3%83%90%E3%82%B7%E3%83%AA%E3%82%AD%E3%82%B7%E3%83%9E%E3%83%96BazyliksymabBasiliximab%D0%91%D0%B0%D0%B7%D0%B8%D0%BB%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1BasiliksimabBasiliksimab%D0%91%D0%B0%D0%B7%D0%B8%D0%BB%D1%96%D0%BA%D1%81%D0%B8%D0%BC%D0%B0%D0%B1BasiliximabQ418702
about
P3781
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious UveitisEvaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsEfficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney TransplantationA Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant RecipientsSafety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal DysfunctionSafety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsSteroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive RegimenRadiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin LymphomaThymoglobulin Induction in Kidney Transplant RecipientsDC Migration Study for Newly-Diagnosed GBMOpen-label, Multi-center, Single Arm, Phase 4 Trial (DoSAKOM)Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney TransplantationCombination of Basiliximab and Pegaspargase in the Treatment of ENKTCLStandard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients
P4844
Q61914344-4F7FBFEF-87AF-43F4-AADA-4DC0E348CCF9Q61915461-56DF52A1-19A0-42E9-B999-DF620FBC2458Q61917851-71D9A69B-46C1-44E5-9674-B004C50E159EQ61933594-5A146DE5-9739-4114-9BAE-07A0866B52CDQ61966936-005593E7-2EAE-48EB-9CCE-A32B541D1B76Q62104978-BD46BA88-FB03-4F72-9EC4-D96F15BB312EQ63316648-317D65DA-9EED-46FC-94CE-0A812CD491B3Q63320695-1FD19F96-EFB4-4DED-8361-4B2F9BD18271Q63340376-1C8E17A9-BD93-4007-A59C-52EE5F3041B8Q63590530-65FD982C-4468-4FA0-AFF1-4D3BE307B59AQ63593446-6A8F6499-6E81-492D-AAE8-FD41A8194977Q63595291-FB3C9C0B-964A-4685-A9CC-2A0F19A5D2F9Q90693488-E6F2D774-2C3E-432F-BE1F-0C1597AE3069Q95718381-9B51CA9D-F798-4681-B5D8-3FD683E6586F
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Basiliksimab
@sh
Basiliksimab
@sr
Basiliximab
@de
Basiliximab
@en
Basiliximab
@nl
Basiliximab
@vi
Bazyliksymab
@pl
basiliximab
@es
basiliximab
@fr
basiliximab
@it
type
label
Basiliksimab
@sh
Basiliksimab
@sr
Basiliximab
@de
Basiliximab
@en
Basiliximab
@nl
Basiliximab
@vi
Bazyliksymab
@pl
basiliximab
@es
basiliximab
@fr
basiliximab
@it
altLabel
Basiliksimab
@pl
Bazyliksimab
@pl
CHI-621
@en
CHI621
@en
Ig gamma-1 chain C region
@en
SDZ-CHI-621
@en
Simulect
@it
Simulect
@pl
chimeric mouse-human antiCD25
@en
Симулект
@ru
prefLabel
Basiliksimab
@sh
Basiliksimab
@sr
Basiliximab
@de
Basiliximab
@en
Basiliximab
@nl
Basiliximab
@vi
Bazyliksymab
@pl
basiliximab
@es
basiliximab
@fr
basiliximab
@it
P31
P486
P592
P6366
P646
P2115
N0000148568
P2167
P2275
basiliximab
@en
P231
179045-86-4
P267
P3345
P3780
P486
P592
CHEMBL1201439
P6366
2781307858
P646
P652
9927MT646M
P7830
Basiliximab